诊断学理论与实践2023，Vol.22Issue(5)：421-428,8.DOI:10.16150/j.1671-2870.2023.05.002
第5版世界卫生组织造血淋巴肿瘤MDS和AML分类更新解读
Interpretation of the 5th edition of the WHO classification of haematolymphoid tumours on MDS and AML
叶向军 1卢兴国2
作者信息
- 1. 浙江大学附属第四医院检验科,浙江 义乌 322000
- 2. 云康血液病整合诊断中心,广东 广州 510700
- 折叠
摘要
Abstract
In 2022,the World Health Organization(WHO)proposed the 5th edition of the WHO Classification of Haematolymphoid Tumours(referred to as the 5th ed.WHO classification)based on the accumulated research results and clinical application progress in related fields after the revised 4th Edition of the WHO classification.Myelodysplastic neo-plasms/syndrome(MDS)and acute myeloid leukemia(AML)in the 5th ed.edition of the WHO classification.In practice in WHO classification has major changes from the revised 4th,it is of great significance for clinical disease diagnosis and treatment,as well as disease registration and scientific research.This article is interpreted based on the fifth edition of the classification published in the journal Leukemia and online ahead of print version on the official website of the Interna-tional Agency for Research on Cancer.关键词
第5版WHO造血和淋巴肿瘤分类/骨髓增生异常肿瘤/急性髓系白血病Key words
5th edition of the WHO Classification of Haematolymphoid Tumours/Myelodysplastic neoplasms/Acute myeloid leukemia分类
医药卫生引用本文复制引用
叶向军,卢兴国..第5版世界卫生组织造血淋巴肿瘤MDS和AML分类更新解读[J].诊断学理论与实践,2023,22(5):421-428,8.
